Cyxone receives notice of patent approval for immunosuppressant treatment with cyclotide T20K

Cyxone announced today that the European Patent Office (EPO), has issued its formal intention to approve the company’s patent application regarding the company’s use of cyclotides as immunosuppressive drugs. The approval will strengthen the company’s patent portfolio and ensures the protection of the candidate T20K, which demonstrates beneficial pharmacological effect in preclinical studies against autoimmune diseases, such as multiple sclerosis (MS).Cyxone focuses on developing drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related